Kymera Therapeutics KYMR Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $144.09M-59.6% | $357.01M+216% | $112.95M-66.4% | $335.82M+273% | $89.97M-25.2% | ||
| $506.84M+3.2% | $491.27M+25.1% | $392.73M+19.1% | $329.63M-11.7% | $373.18M+1.3% | ||
| $5.81M+0.2% | $5.8M+0.2% | $5.79M-0.5% | $5.82M+0.2% | $5.81M+0.2% | ||
| $26.5M+15.5% | $22.94M+1.4% | $22.62M-1.2% | $22.88M+28.5% | $17.8M-17.3% | ||
| —— | —— | $0— | $0-100% | $20M+2,012% | ||
| $677.43M-22.2% | $871.21M+64.9% | $528.3M-27.5% | $728.33M+45.4% | $500.95M-1.8% | ||
| $41.62M-3.6% | $43.18M-4.3% | $45.13M-7.1% | $48.57M-1.2% | $49.17M-2.5% | ||
| $41.74M-1.5% | $42.35M-1.4% | $42.95M-6.7% | $46.05M-1.5% | $46.73M-1.4% | ||
| $7.7M-15.5% | $9.11M+33.5% | $6.83M+46.1% | $4.68M+41.1% | $3.31M+69.9% | ||
| $894.72M+16.0% | $771.16M+63.0% | $473.06M+58.9% | $297.63M-4.7% | $312.34M-13.8% | ||
| $1.67B-4.2% | $1.74B+58.1% | $1.1B-2.6% | $1.13B+23.2% | $918.31M-6.1% | ||
| $12.84M+220% | $4.02M-27.1% | $5.51M-4.8% | $5.78M-43.7% | $10.26M+71.4% | ||
| $976K+303% | $242K-40.7% | $408K+249% | $117K-86.9% | $893K+300% | ||
| $0-100% | $22.93M-1.5% | $23.28M-41.8% | $40M+249% | $11.48M-15.5% | ||
| $1.7M-6.3% | $1.82M-4.0% | $1.89M-0.5% | $1.9M+21.9% | $1.56M+2.7% | ||
| $12.03M+0.8% | $11.94M+0.7% | $11.85M+0.7% | $11.77M+0.7% | $11.68M+0.8% | ||
| $1.7M-6.3% | $1.82M-4.0% | $1.89M-0.5% | $1.9M+21.9% | $1.56M+2.7% | ||
| —— | —— | —— | —— | —— | ||
| $62.64M-24.7% | $83.21M+16.3% | $71.58M-18.2% | $87.54M+48.4% | $58.99M-13.0% | ||
| $65.59M-2.2% | $67.03M-2.1% | $68.45M-2.0% | $69.84M-1.9% | $71.18M-1.7% | ||
| $2.85M-13.0% | $3.28M-11.3% | $3.69M-10.2% | $4.11M+18.6% | $3.47M-7.4% | ||
| $77.62M-1.7% | $78.98M-1.7% | $80.3M-1.6% | $81.6M-1.5% | $82.86M-1.4% | ||
| $1.15M-21.3% | $1.46M-19.0% | $1.8M-18.5% | $2.21M+16.0% | $1.91M-14.3% | ||
| $129.38M-20.7% | $163.15M+4.7% | $155.79M-2.4% | $159.59M+20.8% | $132.08M-7.3% | ||
| $0— | —— | —— | —— | —— | ||
| $8K0.0% | $8K+14.3% | $7K0.0% | $7K0.0% | $7K0.0% | ||
| $2.68B+1.3% | $2.64B+37.4% | $1.92B+3.0% | $1.87B+16.3% | $1.61B+0.9% | ||
| -$1.14B-6.5% | -$1.07B-8.9% | -$978.98M-9.2% | -$896.81M-9.3% | -$820.19M-8.7% | ||
| -$4.19M-333% | $1.8M+19.9% | $1.5M+438% | $279K+581% | -$58K+96.1% | ||
| $1.54B-2.5% | $1.58B+66.9% | $946.26M-2.6% | $971.48M+23.6% | $786.23M-5.9% | ||
| $1.67B-4.2% | $1.74B+58.1% | $1.1B-2.6% | $1.13B+23.2% | $918.31M-6.1% | ||
| $506.84M+3.2% | $491.27M+25.1% | $392.73M+19.1% | $329.63M-11.7% | $373.18M+1.3% | ||
| $7.7M-15.5% | $9.11M+33.5% | $6.83M+46.1% | $4.68M+41.1% | $3.31M+69.9% | ||
| $41.74M-1.5% | $42.35M-1.4% | $42.95M-6.7% | $46.05M-1.5% | $46.73M-1.4% | ||
| $894.72M+16.0% | $771.16M+63.0% | $473.06M+58.9% | $297.63M-4.7% | $312.34M-13.8% | ||
| $41.74M-1.5% | $42.35M-1.4% | $42.95M-6.7% | $46.05M-1.5% | $46.73M-1.4% | ||
| $7.7M-15.5% | $9.11M+33.5% | $6.83M+46.1% | $4.68M+41.1% | $3.31M+69.9% | ||
| $41.74M-1.5% | $42.35M-1.4% | $42.95M-6.7% | $46.05M-1.5% | $46.73M-1.4% | ||
| $7.7M-15.5% | $9.11M+33.5% | $6.83M+46.1% | $4.68M+41.1% | $3.31M+69.9% | ||
| —— | —— | —— | —— | —— | ||
| $35.1M-17.0% | $42.27M+47.6% | $28.64M+2.4% | $27.98M+21.0% | $23.12M-33.7% | ||
| $35.1M-17.0% | $42.27M+47.6% | $28.64M+2.4% | $27.98M+21.0% | $23.12M-33.7% | ||
| $976K+303% | $242K-40.7% | $408K+249% | $117K-86.9% | $893K+300% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $82.17M-2.3% | $84.07M-2.1% | $85.89M-2.0% | $87.61M-0.3% | $87.89M-1.6% | ||
| $2.68B+1.3% | $2.64B+37.4% | $1.92B+3.0% | $1.87B+16.3% | $1.61B+0.9% | ||
| $8K0.0% | $8K+14.3% | $7K0.0% | $7K0.0% | $7K0.0% | ||
| $0— | —— | —— | —— | —— | ||
| $1.7M-6.3% | $1.82M-4.0% | $1.89M-0.5% | $1.9M+21.9% | $1.56M+2.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Kymera Therapeutics's total assets?
- Kymera Therapeutics (KYMR) holds $1.7B in total assets, up 81.8% year over year.
- How much debt does Kymera Therapeutics have?
- Kymera Therapeutics carries $82.2M in total debt against $1.5B of shareholders' equity, a debt-to-equity ratio of 0.05.
- How much cash does Kymera Therapeutics have?
- Kymera Therapeutics holds $144.1M in cash and equivalents.
- Can Kymera Therapeutics cover its short-term obligations?
- Its current ratio is 10.81 — current assets exceed current liabilities.
- Where does Kymera Therapeutics's balance sheet data come from?
- Every line is extracted from Kymera Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
